RT Journal Article
SR Electronic
T1 Conflict of interest among Italian medical oncologists: a national survey
JF BMJ Open
JO BMJ Open
FD British Medical Journal Publishing Group
SP e020912
DO 10.1136/bmjopen-2017-020912
VO 8
IS 6
A1 Andrea DeCensi
A1 Gianmauro Numico
A1 Enzo Ballatori
A1 Fabrizio Artioli
A1 Mario Clerico
A1 Luisa Fioretto
A1 Virginia Livellara
A1 Benedetta Ruggeri
A1 Maurizio Tomirotti
A1 Claudio Verusio
A1 Fausto Roila
A1 ,
YR 2018
UL http://bmjopen.bmj.com/content/8/6/e020912.abstract
AB Objectives To assess Italian medical oncologists’ opinion on the implications of conflict of interest (COI) on medical education, care and research, and to evaluate their direct financial relationships.Design National cross-sectional survey conducted between March and April 2017 among Italian oncologists.Setting Online survey sponsored by the Italian College of Medical Oncology Chiefs through its website.Participants Italian oncologists who filled out an anonymous questionnaire including 19 items and individual and working characteristics.Main outcome measure The proportion of medical oncologists perceiving COI as an outstanding issue and those receiving direct payments from industry.Results There were 321 respondents, representing 13% of Italian tenured medical oncologists. Overall, 62% declared direct payments from the pharmaceutical industry in the last 3 years. Sixty-eight per cent felt the majority of Italian oncologists have a COI with industry, but 59% suppose this is not greater than that of other specialties. Eighty-two per cent consider that most oncology education is supported by industry. More than 75% believe that current allocation of industry budget on marketing and promotion rather than research and development is unfair, but 75% consider it appropriate to receive travel and lodging hospitality from industry. A median net profit margin of €5000 per patient enrolled in an industry trial was considered appropriate for the employee institution. Sixty per cent agree to receive a personal fee for patients enrolled in industry trials, but 79% state this should be reported in the informed consent. Over 90% believe that scientific societies should publish a financial report of industry support. Finally, 79% disagree to being a coauthor of an article written by a medical writer when no substantial scientific contribution is made.Conclusions Among Italian oncologists COI is perceived as an important issue influencing costs, education, care and science. A more rigorous policy on COI should be implemented.